12 Dec, 11:49 - Indian

SENSEX 81432.78 (-0.11)

Nifty 50 24600.1 (-0.17)

Nifty Bank 53367.95 (-0.04)

Nifty IT 45819.35 (1.03)

Nifty Midcap 100 59121 (-0.29)

Nifty Next 50 73239.2 (-0.07)

Nifty Pharma 22232.3 (-0.32)

Nifty Smallcap 100 19524.25 (-0.68)

12 Dec, 11:49 - Global

NIKKEI 225 39849.14 (1.21)

HANG SENG 20480.16 (1.61)

S&P 6097.75 (-0.11)

Login/Signup

You are Here : Home > Research

08-May-2024

Dr Reddys Laboratories

NP up 36.42%

'For the quarter ending March 2024, consolidated net sales (including other operating income) of Dr Reddys Laboratories has increased 12.65% to Rs 7113.8 crore compared to quarter ended March 2023.  Sales of Pharmaceutical Services segment has gone up 12.76% to Rs 1,172.50 crore (accounting for 15.75% of total sales).  Sales of Global Generics segment has gone up 12.88% to Rs 6,128.90 crore (accounting for 82.33% of total sales).  Sales of Others segment has gone up 53.71% to Rs 143.10 crore (accounting for 1.92% of total sales).  Inter-segment sales rose Rs 247.40 crore to Rs 330.70 crore.  

Profit before interest, tax and other unallocable items (PBIT) has jumped 15.23% to Rs 4,148.80 crore.  PBIT of Pharmaceutical Services segment rose 19.24% to Rs 234.90 crore (accounting for 5.66% of total PBIT).  PBIT of Global Generics segment rose 13.25% to Rs 3,793.70 crore (accounting for 91.44% of total PBIT).&nb...



Pleaselogin & subscribe to view the full report.

More Reports
More Reports View Company Information